Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sorafenib in KRAS-mutant advanced non-small cell lung cancer
NL-OMON25401Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoint: Disease control rate. Started May 2010; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON25401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25401.